101 related articles for article (PubMed ID: 7562532)
1. Mu-opioid receptor regulation during opioid tolerance and supersensitivity in rat central nervous system.
Diaz A; Ruiz F; Flórez J; Hurlé MA; Pazos A
J Pharmacol Exp Ther; 1995 Sep; 274(3):1545-51. PubMed ID: 7562532
[TBL] [Abstract][Full Text] [Related]
2. Regulation of dihydropyridine-sensitive Ca++ channels during opioid tolerance and supersensitivity in rats.
Díaz A; Ruíz F; Flórez J; Pazos A; Hurlé MA
J Pharmacol Exp Ther; 1995 Sep; 274(3):1538-44. PubMed ID: 7562531
[TBL] [Abstract][Full Text] [Related]
3. Autoradiographic mapping of mu-opioid receptors during opiate tolerance and supersensitivity in the rat central nervous system.
Díaz A; Pazos A; Flórez J; Hurlé MA
Naunyn Schmiedebergs Arch Pharmacol; 2000 Aug; 362(2):101-9. PubMed ID: 10961371
[TBL] [Abstract][Full Text] [Related]
4. Supersensitivity to mu-opioid receptor-mediated inhibition of the adenylyl cyclase pathway involves pertussis toxin-resistant Galpha protein subunits.
Mostany R; Díaz A; Valdizán EM; Rodríguez-Muñoz M; Garzón J; Hurlé MA
Neuropharmacology; 2008 May; 54(6):989-97. PubMed ID: 18384820
[TBL] [Abstract][Full Text] [Related]
5. Cross-tolerance between mu- and kappa-opioid agonists in the guinea pig ileum myenteric plexus.
Garaulet JV; Laorden ML; Milanés MV
J Pharmacol Exp Ther; 1994 Jun; 269(3):993-9. PubMed ID: 8014886
[TBL] [Abstract][Full Text] [Related]
6. Opioid tolerance and supersensitivity induce regional changes in the autoradiographic density of dihydropyridine-sensitive calcium channels in the rat central nervous system.
Díaz A; Flórez J; Pazos A; Hurlé MA
Pain; 2000 Jun; 86(3):227-235. PubMed ID: 10812252
[TBL] [Abstract][Full Text] [Related]
7. Involvement of the cyclic AMP system in the switch from tolerance into supersensitivity to the antinociceptive effect of the opioid sufentanil.
Hurlé MA; Goirigolzarri I; Valdizán EM
Br J Pharmacol; 2000 May; 130(1):174-80. PubMed ID: 10781014
[TBL] [Abstract][Full Text] [Related]
8. Opioid receptor subtypes differentially modulate serotonin efflux in the rat central nervous system.
Tao R; Auerbach SB
J Pharmacol Exp Ther; 2002 Nov; 303(2):549-56. PubMed ID: 12388635
[TBL] [Abstract][Full Text] [Related]
9. Functional compartmentalization of opioid desensitization in primary sensory neurons.
Samoriski GM; Gross RA
J Pharmacol Exp Ther; 2000 Aug; 294(2):500-9. PubMed ID: 10900225
[TBL] [Abstract][Full Text] [Related]
10. Mu-opioid receptors are involved in the tolerance to nicotine antinociception.
Galeote L; Kieffer BL; Maldonado R; Berrendero F
J Neurochem; 2006 Apr; 97(2):416-23. PubMed ID: 16539669
[TBL] [Abstract][Full Text] [Related]
11. Opioid agonist and antagonist treatment differentially regulates immunoreactive mu-opioid receptors and dynamin-2 in vivo.
Yoburn BC; Purohit V; Patel K; Zhang Q
Eur J Pharmacol; 2004 Sep; 498(1-3):87-96. PubMed ID: 15363980
[TBL] [Abstract][Full Text] [Related]
12. Delta opioid receptor enhancement of mu opioid receptor-induced antinociception in spinal cord.
He L; Lee NM
J Pharmacol Exp Ther; 1998 Jun; 285(3):1181-6. PubMed ID: 9618421
[TBL] [Abstract][Full Text] [Related]
13. Changes in the expression of G protein-coupled receptor kinases and beta-arrestin 2 in rat brain during opioid tolerance and supersensitivity.
Hurlé MA
J Neurochem; 2001 Apr; 77(2):486-92. PubMed ID: 11299311
[TBL] [Abstract][Full Text] [Related]
14. Differential effects of intrathecally administered delta and mu opioid receptor agonists on formalin-evoked nociception and on the expression of Fos-like immunoreactivity in the spinal cord of the rat.
Hammond DL; Wang H; Nakashima N; Basbaum AI
J Pharmacol Exp Ther; 1998 Jan; 284(1):378-87. PubMed ID: 9435201
[TBL] [Abstract][Full Text] [Related]
15. Nitrocinnamoyl and chlorocinnamoyl derivatives of dihydrocodeinone: in vivo and in vitro characterization of mu-selective agonist and antagonist activity.
McLaughlin JP; Hill KP; Jiang Q; Sebastian A; Archer S; Bidlack JM
J Pharmacol Exp Ther; 1999 Apr; 289(1):304-11. PubMed ID: 10087018
[TBL] [Abstract][Full Text] [Related]
16. Opioid peptide receptor studies. 7. The methylfentanyl congener RTI-4614-4 and its four enantiomers bind to different domains of the rat mu opioid receptor.
Lu YF; Xu H; Liu-Chen LY; Chen C; Partilla JS; Brine GA; Carroll FI; Rice KC; Lai J; Porreca F; Sadee W; Rothman RB
Synapse; 1998 Feb; 28(2):117-24. PubMed ID: 9450512
[TBL] [Abstract][Full Text] [Related]
17. Role of cAMP-dependent protein kinase (PKA) in opioid agonist-induced mu-opioid receptor downregulation and tolerance in mice.
Shen J; Benedict Gomes A; Gallagher A; Stafford K; Yoburn BC
Synapse; 2000 Dec; 38(3):322-7. PubMed ID: 11020235
[TBL] [Abstract][Full Text] [Related]
18. Functional reduction in mu-opioidergic system in the spinal cord under a neuropathic pain-like state following chronic ethanol consumption in the rat.
Narita M; Miyoshi K; Narita M; Suzuki T
Neuroscience; 2007 Feb; 144(3):777-82. PubMed ID: 17156932
[TBL] [Abstract][Full Text] [Related]
19. A single residue, Lys108, of the delta-opioid receptor prevents the mu-opioid-selective ligand [D-Ala2,N-MePhe4,Gly-ol5]enkephalin from binding to the delta-opioid receptor.
Minami M; Nakagawa T; Seki T; Onogi T; Aoki Y; Katao Y; Katsumata S; Satoh M
Mol Pharmacol; 1996 Nov; 50(5):1413-22. PubMed ID: 8913373
[TBL] [Abstract][Full Text] [Related]
20. In vivo pharmacological characterization of SoRI 9409, a nonpeptidic opioid mu-agonist/delta-antagonist that produces limited antinociceptive tolerance and attenuates morphine physical dependence.
Wells JL; Bartlett JL; Ananthan S; Bilsky EJ
J Pharmacol Exp Ther; 2001 May; 297(2):597-605. PubMed ID: 11303048
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
